Please assess the completion status of the following clinical trial:

Trial Title: Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have participated and discontinued in the previous PAH placebo controlled study due to clinical worsening on placebo or tadalafil 2.5 mg, 10mg, or 20 mg~* Must have completed Week 16 of the previous PAH study and had either no clinical worsening or became clinically worse at the Week 16 visit on placebo or tadalafil 2.5 mg, 10mg, or 20 mg~* Females who have a negative urine pregnancy test and are willing to use 2 types of birth control~* Be 12 years or older (country specific regulations apply) with parental approval~Exclusion Criteria:~* Participated in the placebo controlled study and had clinical worsening on 40 mg tadalafil~* Have left-sided heart disease~* Have a musculoskeletal disorder that limits being able to get around~* Nitrate use~* Certain current systemic treatments

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 20 mg tadalafil (Type: ACTIVE_COMPARATOR): 20 milligram (mg) tadalafil taken once a day
- 40 mg tadalafil (Type: ACTIVE_COMPARATOR): 40 mg tadalafil tablet taken once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).